SOT102 for Gastric and Pancreatic Adenocarcinoma
(CLAUDIO-01 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a new drug called SOT102 to treat patients with advanced or metastatic pancreatic cancer. It aims to find the best dose and see how well the drug works alone or with other standard treatments.
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop your current medications. However, if you are on corticosteroids or anticonvulsants for central nervous system metastases, you may not be eligible. It's best to discuss your specific medications with the trial team.
What safety data is available for SOT102 treatment?
Is the drug SOT102 a promising treatment for gastric and pancreatic cancer?
What data supports the idea that SOT102 for Gastric and Pancreatic Adenocarcinoma is an effective treatment?
The available research does not provide specific data on the effectiveness of SOT102 for treating gastric and pancreatic adenocarcinoma. Instead, it focuses on other aspects of gastric cancer, such as potential biomarkers and genetic factors. Without direct evidence or comparisons to other treatments, we cannot conclude that SOT102 is effective based on the provided information.1112131415
Who Is on the Research Team?
Josep Tabernero, MD, PhD
Principal Investigator
Vall d'Hebron University Hospital (HUVH)
Are You a Good Fit for This Trial?
This trial is for adults with advanced or metastatic gastric or pancreatic adenocarcinoma. They must have tried at least two prior therapies (one for pancreatic cancer), not be pregnant, and agree to contraception. Excluded are those with severe preexisting conditions, recent major surgery, certain lung diseases, active infections, HIV/hepatitis B/C, or specific genetic deficiencies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation (Part A)
First-in-human, single-agent phase 1 trial of SOT102 in advanced/metastatic pancreatic cancer patients
Combination Treatment (Part B)
Phase 1b dose escalation of SOT102 in combination with nab-paclitaxel/gemcitabine for first-line treatment
Expansion (Part C)
Single-agent SOT102 expansion at RP2D identified in Part A in pancreatic cancer after prior therapies
Combination Expansion (Part D)
SOT102 in combination with nab-paclitaxel/gemcitabine for first-line treatment expansion at RP2D identified in Part B
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- SOT102
Find a Clinic Near You
Who Is Running the Clinical Trial?
SOTIO Biotech a.s.
Lead Sponsor
SOTIO Biotech
Lead Sponsor
Sotio Biotech Inc.
Lead Sponsor